Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2011

View Archived Issues

Ajinomoto synthesizes novel IL-12 and/or IL-23 production inhibitors

First two stages complete in phase IIb INO-8875 trial in glaucoma

PET tracer [18F]-SNUBH-NM-333 shows promise in diagnosis of Alzheimer's disease

GlaxoSmithKline histamine H3 receptor antagonist shows moderate activity in Alzheimer's disease

New prostanoid EP2 receptor agonists reported by Japanese company

Celgene discloses novel inhibitors of TNF-alpha production and/or phosphodiesterase 4

Novel agents for schizophrenia disclosed by Takeda

Mochida Pharmaceutical prepares new free fatty acid FFA1 receptor agonists

Sanofi researchers describe new tryptase beta inhibitor prodrugs

Potent PTP-1B-targeted antisense therapy enters phase I trial in type 2 diabetes

Enrollment begins in pilot study of Repligen's RG-1068 to improve detection of pancreatic cancer

EMA's CHMP recommends approval of dexdor

Takeda discloses preclinical data on new small-molecule GSK-3 inhibitor for Alzheimer's disease

ACS-84 evaluated in rat model of Parkinson's disease

Phase I safety data on SAM-760 in healthy young and elderly subjects

Acacia Pharma initiates phase II study of locally administered xerostomia drug

Positive CHMP opinion for Incivo

Janssen Biotech receives FDA complete response letter regarding Simponi

Biotie Therapies begins phase I imaging trial of SYN-120

CHMP makes recommendations following review of pioglitazone-containing medicines

Tarceva recommended for E.U. approval as first-line therapy in distinct type of lung cancer

FDA committee recommends new approval for Remicade

Afinitor recommended for new European approval

CHMP issues opinion on Zytiga in prostate cancer

R-Tech Ueno amends protocol of its phase I trial in eyelash hypotrichosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...